share_log

The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies

Benzinga Real-time News ·  Jun 27, 2022 10:54

Here's a roundup of top developments in the biotech space over the last 24 hours:

Stocks In Focus

EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer Therapies

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Enhertu (trastuzumab deruxtecan) and Lynparza (olaparib) for breast cancer settings.

Enhertu is being jointly developed and commercialized byAstraZeneca Plc(NASDAQ:AZN) andDaiichi Sankyo(OTC:DSNKY).

Lynparza is jointly developed and commercialized by AstraZeneca andMerck & Co Inc(NYSE:MRK).

Ipsen Buys Epizyme To Bolster Cancer Portfolio

Ipsen SA...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment